Sandra Leung Sells 156,582 Shares of Bristol-Myers Squibb Company (BMY) Stock

Bristol-Myers Squibb Company (NYSE:BMY) EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Bristol-Myers Squibb Company (BMY) traded down $0.45 on Tuesday, reaching $62.02. The company’s stock had a trading volume of 4,828,715 shares, compared to its average volume of 8,452,799. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a market capitalization of $102,310.00, a PE ratio of 21.36, a P/E/G ratio of 2.40 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter last year, the business posted $0.77 EPS. Bristol-Myers Squibb’s quarterly revenue was up 6.7% on a year-over-year basis. equities analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

BMY has been the topic of several research analyst reports. Hilliard Lyons cut Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price on the stock. in a report on Tuesday, September 12th. Goldman Sachs Group reiterated a “buy” rating and issued a $65.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Wednesday, November 1st. SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Finally, Barclays raised their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $64.93.

A number of institutional investors and hedge funds have recently modified their holdings of BMY. Massey Quick Simon & CO. LLC raised its position in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the period. Horan Capital Advisors LLC. acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $122,000. Tradewinds Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the period. Atlantic Trust LLC acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $111,000. Finally, AllSquare Wealth Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $134,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/05/sandra-leung-sells-156582-shares-of-bristol-myers-squibb-company-bmy-stock.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply